ClinicalTrials.gg
Not yet recruitingNCT07172815Updated Sep 15, 2025

PDE5 Inhibitor for Alzheimer's Disease

A Phase 2 interventional study of tadalafil and Placebo in Alzheimer Disease, sponsored by Imperial College London. Not yet recruiting. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Imperial College London · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Alzheimer Disease by Imperial College London — 6 open to participants now, 7 under way, 1 of them phase 3. Alzheimer Disease · Imperial College London.

Started
2025
with 3 others
Phase 2
4 of 11
3 open now
Registered
8th of 11
by date

Among the 11 studies in Alzheimer Disease by Imperial College London, this one is one of 4 that started in 2025, is one of 4 in phase 2, and was the 8th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

6 of the 11 studies in Alzheimer Disease by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by Imperial College London, or all of them as a file.
02

Study summary

Alzheimer's disease is the most common cause of dementia in the elderly population. The disease is characterised by the presence of abnormal proteins in the brain, primarily β-amyloid (Aβ) and tau. Recent evidence suggests that Phosphodiesterase-5 (PDE-5) enzyme inhibitors may hold therapeutic promise in the treatment of early AD. Findings showed that daily low-dose tadalafil (a PDE5 inhibitor that can cross the BBB) administration in patients with erectile dysfunction and MCI increased relative regional cerebral blood flow in the postcentral gyrus, precuneus, and brainstem. However, the long-term effects of tadalafil on AD progression and biomarkers are not known. However, there is limited evidence regarding its safety and efficacy in AD patients. The primary objective of this study is to assess the safety and tolerability of long-term (1 year) tadalafil treatment in patients who are Aβ-positive MCI and early AD based on NIA-AA criteria. Additionally, the secondary objective of this study is to assess the change in cognitive performance from baseline to follow-up, evaluated using neuropsychometric testing, in MCI and AD patients who are undergoing treatment with tadalafil for 1 year.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimers
  • PDE5 Inhibitors
  • Blood Brain Barrier Dysfunction
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving and capacity to give .
  2. An individual who can act as a reliable study partner with regular contact.
  3. Participants must meet the clinical criteria of MCI or AD.
  4. Age from 50 years.
  5. (MMSE) score of 22-28.
  6. Rosen Modified Hachinski Ischemic score ≤4.
  7. Fluency in English and evidence of adequate premorbid intellectual functioning
  8. Likely to be able to participate in all scheduled evaluations and complete all required tests.

Exclusion criteria

Exclusion Criteria:

  1. Any to the use of tadalafil.
  2. Significant neurological disease other than MCI due to AD that may affect cognition.
  3. MRI/CT showing unambiguous aetiological evidence of cerebrovascular disease.
  4. Current presence of a major psychiatric disorder.
  5. Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study.
  6. Any previous enrolment in clinical trials within the last 3 months.
  7. History of epilepsy, where seizures or treatment could have contributed to cognitive impairment.
  8. ST Elevation Myocardial infarction within the last 1 year.
  9. History of cancer within the last 5 years, except localised skin cancer.
  10. Other clinically significant abnormality on physical, neurological or laboratory examination that could compromise the study or be detrimental to the patient.
  11. History of alcohol or drug dependence or abuse within the last 2 years.
  12. Current use of narcotic medications which could affect cognition.
  13. Patients who have been involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in that trial.
  14. Women of .
  15. Any contraindications to MRI scanning, including contraindications for the use of contrast agents, such as renal failure with the estimated of less than 30 ml/minute or known allergy to gadolinium-based contrast agents.
  16. to PDE-5 inhibitors.
  17. Patients who are taking nitrates (see detailed list of nitrate medications in section 7.5).
  18. Severe cardiac diseases.
  19. Patients with unstable angina or angina occurring during exercise or patients with symptomatic coronary artery disease.
  20. Patients with Class 2 or greater heart failure in the last 6 months.
  21. Patients with uncontrolled arrhythmias, hypotension (\< 90/50 mmHg), or uncontrolled hypertension.
  22. Patients with a stroke within the last 6 months.
  23. Patients with pericardial constriction.
  24. Patients with life-threatening arrhythmias.
  25. Patients with severe renal impairment, defined by eGFR \<30 mL/min/1.73 m² or the need for dialysis, and severe hepatic Impairment or any evidence of hepatic failure.
  26. Any other contraindication listed in SmPC.
  27. Patients who take one or more of the following medications: PDE-5 inhibitors other than tadalafil, any other drugs other than tadalafil, potent inhibitors of (see detailed list of drugs and consumables in section 7.5), any anti-amyloid or anti-tau therapies, any other investigational therapies for Alzheimer's disease, and any therapy that may affect Alzheimer's disease, as per the judgement of the Investigator.
  28. [Only applicable for those agreeing to undertake an optional lumbar puncture] Any contraindications of lumbar puncture, including raised intracranial pressure (ICP) with suspected mass effect, skin infections at the puncture site, suspected spinal epidural abscesses, and cellulitis. Individuals with bleeding disorders that may increase the risk of bleeding (e.g. known bleeding diathesis, anticoagulant therapy, thrombocytopenia, abnormal coagulation parameters like prolonged (PT), prolonged activated Partial Thromboplastin Time (aPTT), and abnormal International Normalized Ratio (INR) will be excluded from having lumbar puncture.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
244 participants (estimated)

Study arms

  • Placebo comparator
    Active drug: PDE5 inhibitor

    Drug: tadalafil

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Drugtadalafil

    Once daily dose of Tadalafil will be commenced at 10 mg for 2 weeks, followed by an increase to 20 mg for another 2 weeks and finally increased to 40 mg.

  • DrugPlacebo

    Matched Placebo will be taken once daily.

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of long-term (1 year) tadalafil treatment in MCI and early AD patients.

    To assess the safety and tolerability of long-term (1 year) tadalafil treatment in MCI and early AD patients using composite outcome measure of the adverse events evaluated from the safety measurements. This will be assessed by the number of participants using a composite measure generated from abnormal vital signs, abnormal 12-lead ECG readings, abnormal laboratory (blood) tests, abnormal physical exam findings, and abnormal neurological/psychiatric evaluation.

    Time frame: Data will be collected at screening, baseline, 3-month, 6-month, 9-month and 12-month follow-up.

Secondary outcomes

  1. To assess the change in cognitive performance from baseline to follow-up evaluated using neuropsychometric testing (change in ADAS-Exec) in MCI and AD patients who are undergoing treatment with tadalafil for 1 year.

    Change in combined scores on neuropsychometric testing • ADAS-Exec Z score

    Time frame: Neuropsychometric assessments will be collected at screening, baseline, 6 months and 12 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Aug 2028, 35 months later.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 35 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 15, 2025
StartEst.
Sep 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07172815
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Sep 2025 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Sep 15, 2025

Study contacts

Paul Edison, MD, MPhil, PhD, FRCP, FRCPI
Contact
paul.edison@imperial.ac.uk
+44 7785541923
Hyacinth Henry
Contact
hyacinth.henry@imperial.ac.uk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion